Immune drug studied before colon cancer surgery
NCT ID NCT03984578
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 17 times
Summary
This study gave 33 people with colorectal cancer the immune drug pembrolizumab before their surgery. Researchers wanted to see how the drug changed immune activity inside the tumor. The goal was to learn more about how the immune system responds, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
Sengkang General Hospital
Singapore, 544886, Singapore
-
Singapore General Hospital
Singapore, 169608, Singapore
Conditions
Explore the condition pages connected to this study.